With No deviation now established in China, we’re taking a closer look at China’s regulatory landscape and its global connections. Understanding how the NMPA (National Medical Products Administration) is evolving and converging with international standards is essential for any pharma or biotech company operating in the region. This article explores how to harmonize local and global requirements, a key step to supporting our clients in China and worldwide.
China’s pharmaceutical and biotech market has become one of the most dynamic in the world. With significant growth in R&D, manufacturing, and global partnerships, the country is no longer just a production hub, it is shaping the future of life sciences. At the center of this transformation stands the National Medical Products Administration (NMPA), China’s regulatory authority responsible for drug, medical device, and quality system approvals.
For global and local companies alike, navigating NMPA requirements can feel like a balancing act: meeting complex national regulations while also aligning with international standards such as FDA, EMA, ICH, and PIC/S. The good news? There are strategies to harmonize compliance efforts and even turn them into a competitive advantage.
NMPA: A Regulatory Framework in Evolution
The NMPA has undergone major reforms in the past decade. Driven by China’s membership in the International Council for Harmonisation (ICH), regulatory expectations are increasingly aligned with global practices. For example:
Quality risk management (ICH Q9) and pharmaceutical quality systems (ICH Q10) are progressively integrated into Chinese GMP requirements.
The focus has shifted from “checklist validation” to a more science- and risk-based approach, consistent with ASTM E2500 and EU Annex 15.
Data integrity, audit readiness, and documentation traceability are now top priorities during inspections.
Yet, challenges remain. Foreign companies often face hurdles such as documentation in Mandarin, local interpretation of guidelines, and tight inspection timelines. For local Chinese manufacturers expanding globally, the challenge is the opposite: ensuring that NMPA compliance also meets FDA and EMA expectations.
Bridging the Gap with Global Standards
So, how can companies operating in China succeed? The answer lies in building bridges between NMPA and international requirements rather than treating them as separate tracks.
Start with strong URS and risk assessments.
A well-structured User Requirement Specification (URS) combined with a solid System Risk Assessment (SRA) is universally recognized — by NMPA, FDA, and EMA alike. These documents establish the foundation for risk-based commissioning and qualification (C&Q).
Apply ASTM E2500 principles.
The “science- and risk-based” approach reduces unnecessary testing and focuses on what matters for product quality and patient safety. NMPA inspectors are increasingly receptive to this methodology, provided it is clearly documented.
Align global and local documentation.
Maintaining a single, harmonized validation and quality management approach avoids duplication and ensures readiness for inspections by any authority.
The Role of Digital Validation
One of the most effective ways to navigate the dual requirements of NMPA and international regulators is through digital validation platforms.
Data Integrity: Digital systems ensure complete traceability, version control, and secure access — addressing one of NMPA’s main areas of concern.
Audit-Readiness: With centralized digital records, companies can respond quickly to inspection requests, whether from NMPA or FDA.
Efficiency: Automated workflows reduce manual errors and speed up project delivery, crucial for organizations working under tight market timelines.
For example, platforms like Kneat Gx allow teams to manage the full lifecycle of validation documents, from URS to final reports, in a way that satisfies NMPA expectations while also meeting FDA 21 CFR Part 11 and EU Annex 11 requirements.
Key Takeaways for Companies in China
To succeed in today’s regulatory environment, organizations should focus on three priorities:
Harmonize documentation. Build systems that satisfy both NMPA and international regulators, avoiding duplication and ensuring global readiness.
Adopt a risk-based approach. Demonstrate science-based decisions in C&Q, reducing unnecessary workload while strengthening compliance.
Digitalize validation. Move beyond paper to platforms that guarantee data integrity, audit readiness, and efficiency.
China’s regulatory landscape is complex, but not impenetrable. The NMPA is evolving rapidly and increasingly aligns with international standards. For companies willing to embrace a risk-based, digital-first approach, compliance is no longer just about passing inspections — it becomes a driver of speed, quality, and global competitiveness.
In the end, the real challenge is not “How do we comply with NMPA?” but rather “How do we design our systems so that compliance everywhere is built in by default?”
